Get started
Author

Christopher TenHoor

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
1999 · Allan D. Kirk, Linda C. Burkly, et al. · Nature Medicine · 825
Estimation of the Increase in Solubility of Drugs as a Function of Bile Salt Concentration
1996 · Sabena D. Mithani, Vassiliki Bakatselou, et al. · Pharmaceutical Research · 303
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
2017 · Aleena Banerji, Paula Busse, et al. · New England Journal of Medicine · 174
PDF
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
2014 · Jon A. Kenniston, Ryan R. Faucette, et al. · Journal of Biological Chemistry · 125
Pharmacokinetics, Biologic Activity, and Tolerability of Alefacept by Intravenous and Intramuscular Administration
2002 · Ashay K. Vaishnaw, Christopher N. TenHoor · Journal of Pharmacokinetics and Pharmacodynamics · 51
Solubility of Mefenamic Acid Under Simulated Fed- and Fasted-State Conditions
1991 · Christopher N. TenHoor, Vassiliki Bakatselou, et al. · Pharmaceutical Research · 40
Successful Conversion From Conventional Immunosuppression to Anti-cd154 Monoclonal Antibody Costimulatory Molecule Blockade in Rhesus Renal Allograft Recipients1,2
2001 · Clifford S. Cho, Linda C. Burkly, et al. · Transplantation · 39
Reconversion of Fosphenytoin in the Presence of Intestinal Alkaline Phosphatase
1995 · Christopher N. TenHoor, Barbra H. Stewart · Pharmaceutical Research · 17
Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody
2017 · Jon A. Kenniston, Brandy M. Taylor, et al. · Journal of Biological Chemistry · 15
Clinical Pharmacokinetics of Tonapofylline: Evaluation of Dose Proportionality, Oral Bioavailability, and Gender and Food Effects in Healthy Human Subjects
2010 · Zhaoyang Li, Christopher TenHoor, et al. · The Journal of Clinical Pharmacology · 7
Discovery and Characterization of a Fully Human Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Treatment of Plasma Kallikrein-Mediated Edema
2013 · Daniel Sexton, Ryan Faucette, et al. · Journal of Allergy and Clinical Immunology · 5
PDF
Modeling and Analyses to Identify Potential Dosing Regimens of DX-2930 for the Long-Term Prophylaxis of Hereditary Angioedema
2016 · H. James Wedner, Paula J. Busse, et al. · Journal of Allergy and Clinical Immunology · 2
PDF
Discovery and Characterization of a Highly Specific Antibody Inhibitor of Factor XIIa, and the Subsequent Generation of a Factor XIIa/Plasma Kallikrein Bispecific Antibody
2015 · Shauna D Mason, Jon Kenniston, et al. · Blood · 2
Relationship Between Drug Exposure and Clinical Response Observed in the Phase 1b Study of DX-2930 in Subjects with Hereditary Angioedema
2016 · Joshua S. Jacobs, Paula J. Busse, et al. · Journal of Allergy and Clinical Immunology · 1
PDF
Pharmacodynamic Effect of DX-2930 on Plasma Kallikrein in Hereditary Angioedema Patients
2016 · Mark A. Davis-Lorton, Paula J. Busse, et al. · Journal of Allergy and Clinical Immunology · 1
Comparison Of Plasma Kallikrein Inhibition By The Monoclonal Antibody Inhibitor DX-2930 To Endogenous C1-INH
2014 · Daniel Sexton, Jon Kenniston, et al. · Journal of Allergy and Clinical Immunology · 1
PDF
Discovery and Characterization Of a Highly Specific Antibody Inhibitor Of Plasma Kallikrein
2013 · Jon A Kenniston, Daniel J Sexton, et al. · Blood · 1
Successful Conversion From Conventional Immunosuppression to Anti-cd40 Ligand Therapy in a Non-numan Primate Model.
2000 · Stuart J. Knechtle, Linda C. Burkley, et al. · Transplantation · 1
Limitations to the oral absorption of cyclosporine A.
1993 · Christopher TenHoor · Deep Blue (University of Michigan)
Works count: 19
Citation count: 1,610
H-index: 9
I10-index: 9
Year
Topic
Type